Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

2018 ◽  
Vol 88 ◽  
pp. 10-20
Author(s):  
A. Musolino ◽  
F. Falcini ◽  
A. Sikokis ◽  
D. Boggiani ◽  
A. Rimanti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Registry ◽  
Cancer Detection ◽  
Population Based ◽  
Breast Cancer Detection ◽  
Prognostic Impact ◽  
Registry Study ◽  
Her2 Positive ◽  
Interval Breast Cancer

Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study

2012 ◽  
Vol 30 (19) ◽  
pp. 2362-2368 ◽  
Author(s):  
Antonino Musolino ◽  
Maria Michiara ◽  
Giovanni Maria Conti ◽  
Daniela Boggiani ◽  
Marella Zatelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Cancer Registry ◽  
Growth Factor Receptor ◽  
Population Based ◽  
Mammographic Screening ◽  
Registry Study ◽  
Interval Cancers ◽  
Her2 Positive ◽  
Epidermal Growth

Purpose To determine whether human epidermal growth factor receptor 2 (HER2) –positive status is associated with risk of breast cancer diagnosis in the interval between mammographic screening, we estimated the distribution of features of aggressive tumor behavior in a general population with newly diagnosed breast cancer and known screening status. Patients and Methods We evaluated all invasive breast cancers (N = 641) that were systematically collected by the Parma Province Cancer Registry and diagnosed in women age 50 to 69 years from 2004 to 2007. From this population, 292 screen-detected cancers and 48 interval cases with negative screening mammograms on expert rereading (true interval cancers) were selected for study purposes. Unconditional logistic regression adjusted for age and tumor size was used to determine whether interval cancers were associated with selected clinicobiologic characteristics. Results Tumors with a high histologic grade (odds ratio [OR], 1.8; 95% CI, 1.2 to 3.8), high proliferative rate (OR, 2.4; 95% CI, 1.2 to 4.5), negative estrogen receptor status (OR, 1.6; 95% CI, 1.1 to 3.1), or HER2-positive status (OR, 3.4; 95% CI, 1.7 to 7.1) were more likely to be diagnosed in the interval between screening. Women age less than 60 years with HER2-positive breast cancer were four times more likely to be diagnosed in the interval between screening compared with only a two-fold increased risk for older women. Conclusion This population-based cancer registry study demonstrated that HER2-positive tumors account for a substantial proportion of mammographic screening failure. The distribution of biologic characteristics in screen-detected cancers differs from that observed in interval cancers and may account in part for the more aggressive behavior of interval-detected cases.

scholarly journals Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients

BMJ ◽  
2015 ◽  
pp. h4901 ◽  
Author(s):  
Sepideh Saadatmand ◽  
Reini Bretveld ◽  
Sabine Siesling ◽  
Madeleine M A Tilanus-Linthorst
Keyword(s):  
Breast Cancer ◽  
Cancer Detection ◽  
Population Based ◽  
Breast Cancer Detection ◽  
Tumour Stage ◽  
Population Based Study ◽  
Modern Times

scholarly journals Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study

2015 ◽  
Vol 185 (1) ◽  
pp. 189-194 ◽  
Author(s):  
E. M. Walsh ◽  
M. P. Farrell ◽  
C. Nolan ◽  
F. Gallagher ◽  
R. Clarke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Detection ◽  
Brca2 Mutation ◽  
Population Based ◽  
Breast Cancer Detection ◽  
Population Based Study ◽  
Mutation Carriers ◽  
Brca1 Brca2

scholarly journals Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
E. C. Inwald ◽  
O. Ortmann ◽  
F. Zeman ◽  
M. Koller ◽  
F. Hofstädter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Large Population ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%,P=0.006versus 79%,P=0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.

Sign in / Sign up

Export Citation Format

Share Document